FY2026 Earnings Estimate for TWST Issued By William Blair

Twist Bioscience Co. (NASDAQ:TWST - Free Report) - Analysts at William Blair issued their FY2026 earnings per share estimates for shares of Twist Bioscience in a research report issued on Monday, November 18th. William Blair analyst M. Larew expects that the company will earn ($1.50) per share for the year. The consensus estimate for Twist Bioscience's current full-year earnings is ($3.13) per share.

Several other analysts also recently weighed in on the company. Scotiabank boosted their target price on Twist Bioscience from $50.00 to $54.00 and gave the company a "sector outperform" rating in a report on Tuesday. Robert W. Baird lifted their target price on shares of Twist Bioscience from $46.00 to $48.00 and gave the company an "outperform" rating in a report on Tuesday. Barclays cut their target price on Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating for the company in a research note on Tuesday. JPMorgan Chase & Co. upped their price target on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an "underweight" rating in a research note on Monday, August 5th. Finally, Evercore ISI boosted their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an "outperform" rating in a report on Tuesday, October 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $51.78.

Twist Bioscience Price Performance

Shares of TWST traded down $0.35 during mid-day trading on Wednesday, reaching $40.97. The company's stock had a trading volume of 526,634 shares, compared to its average volume of 951,846. The company's 50 day moving average is $43.99 and its 200 day moving average is $46.18. The stock has a market cap of $2.40 billion, a PE ratio of -10.82 and a beta of 1.78. Twist Bioscience has a 12-month low of $23.07 and a 12-month high of $60.90.

Insider Activity

In other Twist Bioscience news, Director Robert Chess sold 3,600 shares of the company's stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $47.26, for a total value of $170,136.00. Following the transaction, the director now directly owns 21,641 shares of the company's stock, valued at $1,022,753.66. This represents a 14.26 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Paula Green sold 3,310 shares of Twist Bioscience stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $43.21, for a total transaction of $143,025.10. Following the completion of the sale, the senior vice president now owns 84,585 shares of the company's stock, valued at approximately $3,654,917.85. This trade represents a 3.77 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 98,118 shares of company stock valued at $4,391,151 in the last 90 days. 3.92% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Twist Bioscience

Several hedge funds and other institutional investors have recently modified their holdings of TWST. Geode Capital Management LLC boosted its holdings in Twist Bioscience by 1.9% in the third quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company's stock worth $61,807,000 after purchasing an additional 26,145 shares during the period. Barclays PLC lifted its holdings in Twist Bioscience by 214.8% in the third quarter. Barclays PLC now owns 153,039 shares of the company's stock worth $6,913,000 after acquiring an additional 104,420 shares during the last quarter. XTX Topco Ltd boosted its stake in Twist Bioscience by 36.7% in the third quarter. XTX Topco Ltd now owns 15,518 shares of the company's stock valued at $701,000 after acquiring an additional 4,169 shares during the period. Wellington Management Group LLP boosted its position in Twist Bioscience by 188.5% during the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company's stock valued at $36,042,000 after purchasing an additional 521,272 shares during the period. Finally, State Street Corp increased its holdings in shares of Twist Bioscience by 19.9% in the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company's stock worth $143,101,000 after acquiring an additional 526,028 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.